Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Alagille syndrome liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Alagille syndrome liver disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Polycystic liver disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Polycystic liver disease strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Caroli syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Caroli syndrome indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Peliosis hepatis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Peliosis hepatis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Focal nodular hyperplasia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Focal nodular hyperplasia strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Hepatic adenoma Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Hepatic adenoma indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
IgG4-related sclerosing cholangitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 IgG4-related sclerosing cholangitis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Acute cholangitis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Acute cholangitis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Choledocholithiasis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Choledocholithiasis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Gallstone disease Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Gallstone disease indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Primary bile acid malabsorption Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Primary bile acid malabsorption strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP.
Latest Hotspot
10 min read
Biliary dyskinesia Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Biliary dyskinesia indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.